KalVista Pharmaceuticals Quarterly Balance Sheets Chart
Quarterly
|
Annual
KalVista Pharmaceuticals Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 | 2024-01-31 | 2023-10-31 | 2023-07-31 | 2023-04-30 | 2023-01-31 | 2022-10-31 | 2022-07-31 | 2022-04-30 | 2022-01-31 | 2021-10-31 | 2021-07-31 | 2021-04-30 | 2021-01-31 | 2020-10-31 | 2020-07-31 | 2020-04-30 | 2020-01-31 | 2019-10-31 | 2019-07-31 | 2019-04-30 | 2019-01-31 | 2018-10-31 | 2018-07-31 | 2018-04-30 | 2018-01-31 | 2017-10-31 | 2017-07-31 | 2017-04-30 | 2017-01-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||||||||||||||||||||||||||
| current assets: | ||||||||||||||||||||||||||||||||||||||||||
| cash and cash equivalents | 124,304,000 | 131,615,000 | 167,288,000 | 41,581,000 | 31,848,000 | 31,789,000 | 23,056,000 | 57,666,000 | 49,409,000 | 56,238,000 | 85,049,000 | 38,585,000 | 37,863,000 | 30,732,000 | 45,577,000 | 46,491,000 | 48,343,000 | 50,592,000 | 17,727,000 | 16,174,000 | 18,014,000 | 15,789,000 | 18,615,000 | 21,719,000 | 30,107,000 | 32,006,000 | 56,345,000 | 121,116,000 | 48,070,000 | 51,055,000 | 58,678,000 | 28,128,000 | 26,456,000 | 30,950,000 | 33,498,000 | 35,208,000 | 36,819,000 | 48,455,000 | 53,723,000 | 59,878,000 | 65,381,000 | 3,181,000 |
| marketable securities | 67,161,000 | 89,002,000 | 85,915,000 | 94,195,000 | 142,424,000 | 178,612,000 | 52,530,000 | 45,506,000 | 73,848,000 | 93,137,000 | 86,636,000 | 83,688,000 | 104,212,000 | 135,470,000 | 149,212,000 | 163,322,000 | 182,288,000 | 198,337,000 | 32,584,000 | 39,700,000 | 46,317,000 | 51,925,000 | 61,955,000 | 71,742,000 | 70,259,000 | 68,805,000 | ||||||||||||||||
| accounts receivable | 1,926,000 | |||||||||||||||||||||||||||||||||||||||||
| research and development tax credit receivable | 561,000 | 1,383,000 | 7,485,000 | 11,082,000 | 9,908,000 | 8,439,000 | 23,011,000 | 19,976,000 | 19,057,000 | 16,568,000 | 11,892,000 | 20,029,000 | 17,248,000 | 14,098,000 | 11,287,000 | 17,399,000 | 13,613,000 | 10,418,000 | 7,589,000 | 14,685,000 | 12,638,000 | 16,527,000 | 14,803,000 | 11,814,000 | 12,625,000 | 11,315,000 | 8,970,000 | 7,032,000 | 5,604,000 | 6,834,000 | 4,989,000 | 3,718,000 | 2,822,000 | 2,250,000 | 2,840,000 | |||||||
| prepaid expenses and other current assets | 11,944,000 | 19,690,000 | 6,671,000 | 5,409,000 | 7,454,000 | 6,850,000 | 5,506,000 | 5,458,000 | 7,528,000 | 6,383,000 | 8,556,000 | 8,914,000 | 11,084,000 | 13,347,000 | 8,388,000 | 7,266,000 | 5,538,000 | 4,917,000 | 4,604,000 | 1,517,000 | 3,256,000 | 4,455,000 | 3,632,000 | 2,617,000 | 2,728,000 | 3,420,000 | 3,946,000 | 1,922,000 | 1,511,000 | 1,491,000 | 2,003,000 | 1,400,000 | 841,000 | 751,000 | 1,217,000 | 605,000 | 1,138,000 | 1,010,000 | 1,222,000 | 1,571,000 | 1,614,000 | 1,127,000 |
| total current assets | 205,896,000 | 241,690,000 | 267,359,000 | 152,267,000 | 191,634,000 | 225,690,000 | 104,103,000 | 128,606,000 | 149,842,000 | 172,326,000 | 192,133,000 | 151,216,000 | 170,407,000 | 193,647,000 | 214,464,000 | 234,478,000 | 249,782,000 | 264,264,000 | 62,504,000 | 72,076,000 | 80,225,000 | 88,696,000 | 99,005,000 | 107,892,000 | 115,719,000 | 115,546,000 | 124,063,000 | 130,070,000 | 55,185,000 | 59,380,000 | 65,710,000 | 34,139,000 | 30,192,000 | 34,248,000 | 37,953,000 | 35,813,000 | 37,957,000 | 49,465,000 | 54,945,000 | 61,449,000 | 66,995,000 | 4,308,000 |
| property and equipment, net of accumulated depreciation of 4,925 and 4,747 | 2,067,000 | |||||||||||||||||||||||||||||||||||||||||
| right of use assets | 5,165,000 | 5,544,000 | 5,440,000 | 5,863,000 | 5,859,000 | 6,920,000 | 7,045,000 | 7,298,000 | 7,571,000 | 7,822,000 | 8,101,000 | 8,365,000 | 8,664,000 | 7,862,000 | 8,180,000 | 6,959,000 | 7,207,000 | 5,758,000 | 1,653,000 | 1,305,000 | 1,480,000 | 1,612,000 | 1,497,000 | 1,634,000 | 1,737,000 | |||||||||||||||||
| other assets | 2,377,000 | 1,548,000 | 1,387,000 | 662,000 | 605,000 | 567,000 | 397,000 | 337,000 | 106,000 | 106,000 | 197,000 | 197,000 | 218,000 | 193,000 | 193,000 | 193,000 | 200,000 | 200,000 | 181,000 | 178,000 | 178,000 | 178,000 | 173,000 | 173,000 | 173,000 | 173,000 | 173,000 | 173,000 | 173,000 | 173,000 | 173,000 | 991,000 | 218,000 | 179,000 | 179,000 | |||||||
| total assets | 215,505,000 | 250,770,000 | 275,993,000 | 160,831,000 | 200,198,000 | 235,404,000 | 113,968,000 | 138,743,000 | 160,332,000 | 183,202,000 | 203,468,000 | 162,838,000 | 182,319,000 | 203,880,000 | 225,052,000 | 243,810,000 | 259,133,000 | 272,013,000 | 66,206,000 | 75,448,000 | 83,902,000 | 92,529,000 | 102,935,000 | 112,064,000 | 119,884,000 | 118,132,000 | 126,525,000 | 132,559,000 | 57,618,000 | 61,389,000 | 66,657,000 | 34,741,000 | 30,784,000 | 34,345,000 | 38,050,000 | 35,863,000 | 38,007,000 | 49,675,000 | 56,791,000 | 62,079,000 | 67,598,000 | 7,712,000 |
| liabilities and stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||
| current liabilities: | ||||||||||||||||||||||||||||||||||||||||||
| accounts payable | 5,869,000 | 4,883,000 | 5,856,000 | 5,198,000 | 10,792,000 | 9,107,000 | 3,101,000 | 4,896,000 | 5,060,000 | 4,817,000 | 1,698,000 | 3,384,000 | 2,908,000 | 3,638,000 | 2,185,000 | 3,159,000 | 1,448,000 | 1,981,000 | 641,000 | 2,173,000 | 1,774,000 | 1,677,000 | 2,951,000 | 2,238,000 | 3,103,000 | 2,860,000 | 2,998,000 | 3,018,000 | 2,345,000 | 1,433,000 | 1,575,000 | 1,040,000 | 1,943,000 | 1,153,000 | 755,000 | 431,000 | 187,000 | 793,000 | 1,460,000 | 1,527,000 | 1,992,000 | 2,545,000 |
| accrued expenses | 18,971,000 | 27,307,000 | 18,315,000 | 15,429,000 | 10,355,000 | 12,398,000 | 14,840,000 | 11,707,000 | 7,950,000 | 9,128,000 | 8,851,000 | 6,910,000 | 5,828,000 | 6,961,000 | 6,450,000 | 6,025,000 | 5,876,000 | 6,930,000 | 5,285,000 | 6,941,000 | 6,170,000 | 5,455,000 | 4,876,000 | 5,029,000 | 4,261,000 | 5,593,000 | 3,408,000 | 2,994,000 | 3,137,000 | 3,087,000 | 2,290,000 | 2,253,000 | 1,692,000 | 1,865,000 | 2,446,000 | 1,431,000 | 1,713,000 | 1,082,000 | 1,327,000 | 1,272,000 | 1,666,000 | 1,832,000 |
| lease liability - current portion | 2,122,000 | 1,977,000 | 1,444,000 | 1,537,000 | 1,264,000 | 1,302,000 | 1,187,000 | 1,148,000 | 1,122,000 | 1,087,000 | 1,057,000 | 1,026,000 | 997,000 | 977,000 | 1,014,000 | 930,000 | 905,000 | 863,000 | 592,000 | 422,000 | 513,000 | 588,000 | 592,000 | 602,000 | 580,000 | |||||||||||||||||
| deferred revenue | 11,413,000 | 11,000,000 | ||||||||||||||||||||||||||||||||||||||||
| total current liabilities | 38,375,000 | 45,167,000 | 25,615,000 | 22,164,000 | 22,411,000 | 22,807,000 | 19,128,000 | 17,751,000 | 14,132,000 | 15,032,000 | 11,606,000 | 11,320,000 | 9,733,000 | 11,576,000 | 9,649,000 | 10,114,000 | 8,229,000 | 9,774,000 | 6,518,000 | 9,536,000 | 8,457,000 | 7,720,000 | 9,762,000 | 10,470,000 | 13,967,000 | 18,052,000 | 18,826,000 | 20,938,000 | 22,903,000 | 23,216,000 | 24,083,000 | 3,513,000 | 3,837,000 | 3,018,000 | 3,201,000 | 1,891,000 | 1,929,000 | 3,854,000 | 4,271,000 | 3,793,000 | 4,167,000 | 11,005,000 |
| long-term liabilities: | ||||||||||||||||||||||||||||||||||||||||||
| lease liability - net of current portion | 4,019,000 | 4,330,000 | 4,338,000 | 4,675,000 | 4,988,000 | 6,015,000 | 6,257,000 | 6,546,000 | 6,865,000 | 7,145,000 | 7,421,000 | 7,705,000 | 8,014,000 | 7,211,000 | 7,467,000 | 6,224,000 | 6,474,000 | 5,046,000 | 1,123,000 | 932,000 | 1,010,000 | 1,057,000 | 926,000 | 1,053,000 | 1,177,000 | |||||||||||||||||
| royalty obligation | 132,321,000 | |||||||||||||||||||||||||||||||||||||||||
| total long-term liabilities | 136,340,000 | 110,212,000 | 105,252,000 | 4,675,000 | 4,988,000 | 6,015,000 | 6,257,000 | 6,546,000 | 6,865,000 | 7,145,000 | 7,421,000 | 7,705,000 | 8,014,000 | 7,211,000 | 7,467,000 | 6,224,000 | 6,474,000 | 5,046,000 | 1,123,000 | 932,000 | 1,010,000 | 1,057,000 | 3,426,000 | 3,807,000 | 4,050,000 | 3,342,000 | 3,666,000 | 4,670,000 | 8,465,000 | 10,920,000 | 14,006,000 | 149,000 | 213,000 | |||||||||
| stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||
| common stock | 27,000 | 27,000 | 27,000 | 27,000 | 27,000 | 27,000 | 1,000 | |||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 50,339,823 at july 31, 2025 and 49,762,048 at april 30, 2025 | 50,000 | |||||||||||||||||||||||||||||||||||||||||
| additional paid-in capital | 760,393,000 | 753,725,000 | 748,231,000 | 689,087,000 | 685,794,000 | 679,754,000 | 516,920,000 | 513,926,000 | 510,591,000 | 507,133,000 | 504,725,000 | 444,588,000 | 441,914,000 | 439,104,000 | 436,313,000 | 432,763,000 | 429,840,000 | 426,437,000 | 212,694,000 | 209,750,000 | 208,442,000 | 207,208,000 | 206,119,000 | 204,950,000 | 203,650,000 | 191,123,000 | 190,067,000 | 189,164,000 | 105,358,000 | 100,011,000 | 99,696,000 | 99,408,000 | 90,036,000 | 89,815,000 | 89,399,000 | 122,873,000 | 122,586,000 | 122,272,000 | 121,904,000 | 121,556,000 | 121,268,000 | 3,989,000 |
| accumulated deficit | -713,266,000 | -653,170,000 | -600,946,000 | -552,437,000 | -510,169,000 | -469,726,000 | -425,077,000 | -396,049,000 | -368,399,000 | -343,082,000 | -316,777,000 | -295,474,000 | -273,217,000 | -250,175,000 | -226,062,000 | -203,595,000 | -183,945,000 | -167,836,000 | -152,880,000 | -142,832,000 | -132,406,000 | -121,592,000 | -115,008,000 | -105,717,000 | -99,814,000 | -92,476,000 | -83,950,000 | -79,994,000 | -76,690,000 | -71,660,000 | -71,003,000 | -65,769,000 | -60,784,000 | -55,855,000 | -51,653,000 | -88,963,000 | -86,577,000 | -79,228,000 | -72,621,000 | -66,962,000 | -61,971,000 | -52,959,000 |
| accumulated other comprehensive loss | -6,387,000 | -5,214,000 | -2,208,000 | -2,701,000 | -2,869,000 | -3,488,000 | -3,294,000 | -3,465,000 | -2,891,000 | -3,060,000 | -3,541,000 | -5,326,000 | -4,150,000 | -3,861,000 | -2,339,000 | -1,720,000 | -1,489,000 | -1,432,000 | -1,267,000 | -1,956,000 | -1,619,000 | -1,882,000 | -1,382,000 | -1,464,000 | -1,987,000 | -1,926,000 | -2,101,000 | -2,236,000 | -2,429,000 | -1,109,000 | -136,000 | -2,571,000 | -2,528,000 | -2,643,000 | -2,907,000 | |||||||
| total stockholders’ equity | 40,790,000 | 95,391,000 | 145,126,000 | 133,992,000 | 172,799,000 | 206,582,000 | 88,583,000 | 114,446,000 | 139,335,000 | 161,025,000 | 184,441,000 | 143,813,000 | 164,572,000 | 185,093,000 | 207,936,000 | 227,472,000 | 244,430,000 | 257,193,000 | 58,565,000 | 64,980,000 | 74,435,000 | 83,752,000 | 89,747,000 | 97,787,000 | 101,867,000 | 96,738,000 | 104,033,000 | 106,951,000 | 26,250,000 | 27,253,000 | 28,568,000 | 31,079,000 | 26,734,000 | 31,327,000 | 34,849,000 | 33,937,000 | 36,036,000 | 43,071,000 | 49,310,000 | 54,621,000 | 59,324,000 | |
| total liabilities and stockholders’ equity | 215,505,000 | 250,770,000 | 275,993,000 | 160,831,000 | 200,198,000 | 235,404,000 | 113,968,000 | 138,743,000 | 160,332,000 | 183,202,000 | 203,468,000 | 162,838,000 | 182,319,000 | 203,880,000 | 225,052,000 | 243,810,000 | 259,133,000 | 272,013,000 | 66,206,000 | 75,448,000 | 83,902,000 | 92,529,000 | 102,935,000 | 112,064,000 | 119,884,000 | 118,132,000 | 126,525,000 | 132,559,000 | 57,618,000 | 61,389,000 | 66,657,000 | 34,741,000 | 30,784,000 | 34,345,000 | 38,050,000 | 35,863,000 | 38,007,000 | 49,675,000 | ||||
| property and equipment | 1,988,000 | 1,807,000 | 2,039,000 | 2,100,000 | 2,227,000 | 2,423,000 | 2,502,000 | 2,813,000 | 2,948,000 | 3,037,000 | 3,060,000 | 3,030,000 | 2,178,000 | 2,215,000 | 2,180,000 | 1,944,000 | 1,791,000 | 1,868,000 | 1,889,000 | 2,019,000 | 2,043,000 | 2,260,000 | 2,365,000 | 2,255,000 | 2,413,000 | 2,289,000 | 2,316,000 | 2,260,000 | 1,836,000 | 774,000 | 602,000 | 592,000 | 97,000 | 97,000 | 160,000 | 805,000 | 362,000 | 374,000 | 329,000 | |||
| deferred royalty obligation | 105,882,000 | 100,914,000 | ||||||||||||||||||||||||||||||||||||||||
| commitments and contingencies | ||||||||||||||||||||||||||||||||||||||||||
| stockholders’ equity: | ||||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 49,762,048 and 42,521,975 as of april 30, 2025 and 2024, respectively | 50,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 49,493,210 at january 31, 2025 and 42,521,975 at april 30, 2024 | 49,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 43,271,501 at october 31, 2024 and 42,521,975 at april 30, 2024 | 43,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 43,081,922 at july 31, 2024 and 42,521,975 at april 30, 2024 | 43,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 42,521,975 and 34,171,138 as of april 30, 2024 and 2023, respectively | 42,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 34,595,623 at january 31, 2024 and 34,171,138 at april 30, 2023 | 34,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 34,421,458 at october 31, 2023 and 34,171,138 at april 30, 2023 | 34,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 34,266,595 at july 31, 2023 and 34,171,138 at april 30, 2023 | 34,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 34,171,138 and 24,550,748 as of april 30, 2023 and 2022, respectively | 34,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 34,127,762 at january 31, 2023 and 24,550,748 at april 30, 2022 | 34,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 24,602,023 at october 31, 2022 and 24,550,748 at april 30, 2022 | 25,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 24,570,872 at july 31, 2022 and 24,550,748 at april 30, 2022 | 25,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 24,550,748 and 24,422,531 at april 30, 2022 and 2021, respectively | 25,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 24,537,094 at january 31, 2022 and 24,422,531 at april 30, 2021 | 24,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 24,443,432 at october 31, 2021 and 24,422,531 at april 30, 2021 | 24,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 24,437,515 at july 31, 2021 and 24,422,531 at april 30, 2021 | 24,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 24,422,531 and 17,845,599 at april 30, 2021 and 2020, respectively | 24,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 18,021,224 at january 31, 2021 and 17,845,599 at april 30, 2020 | 18,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 17,915,515 at october 31, 2020 and 17,845,599 at april 30, 2020 | 18,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 17,880,414 at july 31, 2020 and 17,845,599 at april 30, 2020 | 18,000 | |||||||||||||||||||||||||||||||||||||||||
| deferred revenue - current portion | 1,343,000 | 2,601,000 | 6,023,000 | 9,545,000 | 12,311,000 | 14,769,000 | 17,207,000 | 18,475,000 | 19,996,000 | |||||||||||||||||||||||||||||||||
| deferred revenue - net of current portion | 2,500,000 | 2,754,000 | 2,873,000 | 3,342,000 | 3,666,000 | 4,670,000 | 8,465,000 | 10,862,000 | 13,889,000 | |||||||||||||||||||||||||||||||||
| shares issued and outstanding: 17,845,599 at april 30, 2020 and 17,277,750 at april 30, 2019 | 18,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 17,845,599 at january 31, 2020 and 17,277,750 at april 30, 2019 | 18,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 17,834,126 at october 31, 2019 and 17,277,750 at april 30, 2019 | 18,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 17,815,493 at july 31, 2019 and 17,277,750 at april 30, 2019 | 18,000 | |||||||||||||||||||||||||||||||||||||||||
| capital lease liability - current portion | 54,000 | 109,000 | 157,000 | 214,000 | 221,000 | 222,000 | 220,000 | |||||||||||||||||||||||||||||||||||
| capital lease liability - net of current portion | 58,000 | 117,000 | 149,000 | |||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 17,277,750 at april 30, 2019 and 10,799,895 at april 30, 2018 | 17,000 | |||||||||||||||||||||||||||||||||||||||||
| investments | 54,802,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 17,247,306 at january 31, 2019 and 10,799,895 at april 30, 2018 | 17,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 17,225,167 at october 31, 2018 and 10,799,895 at april 30, 2018 | 17,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 10,799,895 at july 31, 2018 and at april 30, 2018 | 11,000 | |||||||||||||||||||||||||||||||||||||||||
| grants and other receivables | 40,000 | 893,000 | ||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 10,799,895 at april 30, 2018 and 9,713,042 at april 30, 2017 | 11,000 | |||||||||||||||||||||||||||||||||||||||||
| shares authorized: 100,000,000 | ||||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 10,792,646 | 11,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 10,783,631 | 11,000 | |||||||||||||||||||||||||||||||||||||||||
| grants receivable | 73,000 | 297,000 | 398,000 | |||||||||||||||||||||||||||||||||||||||
| capital lease liability | 202,000 | |||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 9,713,042 | 10,000 | |||||||||||||||||||||||||||||||||||||||||
| due to related parties | ||||||||||||||||||||||||||||||||||||||||||
| series b convertible preferred stock, 0.0016 par value | ||||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: none at april 30, 2017 and 8,422,898 at april 30, 2016 | ||||||||||||||||||||||||||||||||||||||||||
| series a convertible preferred stock, 0.0016 par value | ||||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: none at april 30, 2017 and 15,900,000 at april 30, 2016 | ||||||||||||||||||||||||||||||||||||||||||
| total preferred stock | ||||||||||||||||||||||||||||||||||||||||||
| ordinary shares, 0.0016 par value | ||||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: none at april 30, 2017 and 2,167,367 at april 30, 2016 | ||||||||||||||||||||||||||||||||||||||||||
| shares authorized: 100,000,000 at april 30, 2017 | ||||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 9,713,042 at april 30, 2017 and none at april 30, 2016 | 10,000 | |||||||||||||||||||||||||||||||||||||||||
| redeemable convertible preferred stock | ||||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: none at january 31, 2017 and 24,322,898 at april 30, 2016 | ||||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: none at january 31, 2017 and 2,167,367 at april 30, 2016 | ||||||||||||||||||||||||||||||||||||||||||
| shares authorized: 100,000,000 at january 31, 2017 | ||||||||||||||||||||||||||||||||||||||||||
| shares issued and outstanding: 9,713,042 at january 31, 2017 and none at april 30, 2016 | 10,000 | |||||||||||||||||||||||||||||||||||||||||
| restricted cash | 50,000 | 50,000 | 50,000 | 50,000 | 50,000 | 50,000 | 50,000 | |||||||||||||||||||||||||||||||||||
| loan payable | ||||||||||||||||||||||||||||||||||||||||||
| deferred licensing revenue | 29,000 | 29,000 | 29,000 | 29,000 | 29,000 | 29,000 | 29,000 | |||||||||||||||||||||||||||||||||||
| loans payable, net of current portion | 2,701,000 | 3,154,000 | 3,601,000 | 4,036,000 | 3,404,000 | |||||||||||||||||||||||||||||||||||||
| deferred licensing revenue, net of current portion | 35,000 | 42,000 | 49,000 | 56,000 | 64,000 | 71,000 | 78,000 | |||||||||||||||||||||||||||||||||||
| total liabilities | 1,926,000 | 1,971,000 | 6,604,000 | 7,481,000 | 7,458,000 | 8,274,000 | 17,125,000 | |||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value; 5,000,000 shares authorized as of september 30, 2016 and december 31, 2015: no shares issued and outstanding as of september 30, 2016 and december 31, 2015 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value; 5,000,000 shares authorized as of june 30, 2016 and december 31, 2015: no shares issued and outstanding as of june 30, 2016 and december 31, 2015 | ||||||||||||||||||||||||||||||||||||||||||
| loans payable | 1,950,000 | 1,455,000 | 965,000 | 480,000 | 1,075,000 | |||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value; 5,000,000 shares authorized as of march 31, 2016 and december 31, 2015: no shares issued and outstanding as of march 31, 2016 and december 31, 2015 | ||||||||||||||||||||||||||||||||||||||||||
| deferred public offering costs | 2,846,000 | |||||||||||||||||||||||||||||||||||||||||
| liabilities, convertible preferred stock and stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||
| convertible promissory notes | 5,524,000 | |||||||||||||||||||||||||||||||||||||||||
| derivative liability | 2,287,000 | |||||||||||||||||||||||||||||||||||||||||
| preferred stock warrant liability | 349,000 | |||||||||||||||||||||||||||||||||||||||||
| deferred rent, net of current portion | 2,000 | |||||||||||||||||||||||||||||||||||||||||
| convertible preferred stock, 0.001 par value; no shares authorized as of december 31, 2015 and 34,371,305 shares authorized as of december 31, 2014; no shares issued and outstanding as of december 31, 2015 and 8,268,531 shares issued and outstanding as of december 31, 2014 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value; 5,000,000 shares authorized as of december 31, 2015 and none authorized as of december 31, 2014: no shares issued and outstanding as of december 31, 2015 and december 31, 2014 | ||||||||||||||||||||||||||||||||||||||||||
| total liabilities, convertible preferred stock and stockholders’ equity | 56,791,000 | 62,079,000 | 67,598,000 | |||||||||||||||||||||||||||||||||||||||
| convertible preferred stock, 0.001 par value; no shares authorized as of september 30, 2015 and 34,371,305 shares authorized as of december 31, 2014; no shares issued and outstanding as of september 30, 2015 and 8,268,531 shares issued and outstanding as of december 31, 2014 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value; 5,000,000 shares authorized as of september 30, 2015 and none authorized as of december 31, 2014: no shares issued and outstanding as of september 30, 2015 | ||||||||||||||||||||||||||||||||||||||||||
| convertible preferred stock, 0.001 par value; no shares authorized as of june 30, 2015 and 34,371,305 shares authorized as of december 31, 2014; no shares issued and outstanding as of june 30, 2015 and 8,268,531 shares issued and outstanding as of december 31, 2014 | ||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value; 5,000,000 shares authorized as of june 30, 2015 and none authorized as of december 31, 2014: no shares issued and outstanding as of june 30, 2015 | ||||||||||||||||||||||||||||||||||||||||||
| liabilities, convertible preferred stock and stockholders’ deficit | ||||||||||||||||||||||||||||||||||||||||||
| convertible preferred stock, 0.001 par value; 34,371,305 shares authorized, 8,268,531 issued and outstanding at march 31, 2015 and at december 31, 2014 | 39,556,000 | |||||||||||||||||||||||||||||||||||||||||
| stockholders’ deficit | ||||||||||||||||||||||||||||||||||||||||||
| total stockholders’ deficit | -48,969,000 | |||||||||||||||||||||||||||||||||||||||||
| total liabilities, convertible preferred stock and stockholders’ deficit | 7,712,000 | |||||||||||||||||||||||||||||||||||||||||
| license revenue | 7,000 | |||||||||||||||||||||||||||||||||||||||||
| operating expenses: | ||||||||||||||||||||||||||||||||||||||||||
| research and development | 3,902,000 | |||||||||||||||||||||||||||||||||||||||||
| general and administrative | 1,006,000 | |||||||||||||||||||||||||||||||||||||||||
| total operating expenses | 4,908,000 | |||||||||||||||||||||||||||||||||||||||||
| income from operations | -4,901,000 | |||||||||||||||||||||||||||||||||||||||||
| other income: | ||||||||||||||||||||||||||||||||||||||||||
| interest expense | -836,000 | |||||||||||||||||||||||||||||||||||||||||
| other income | 553,000 | |||||||||||||||||||||||||||||||||||||||||
| total other income | -283,000 | |||||||||||||||||||||||||||||||||||||||||
| net income and comprehensive loss | -5,184,000 | |||||||||||||||||||||||||||||||||||||||||
| net income attributable to common stockholders | -5,184,000 | |||||||||||||||||||||||||||||||||||||||||
| net income per share | -7,380 | |||||||||||||||||||||||||||||||||||||||||
| weighted-average common shares outstanding, basic and diluted | 701,980,000 |
We provide you with 20 years of balance sheets for KalVista Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of KalVista Pharmaceuticals. Explore the full financial landscape of KalVista Pharmaceuticals stock with our expertly curated balance sheets.
The information provided in this report about KalVista Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.